Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

It has been 12 yr since the publication of the last World Health Organization (WHO)
classification of tumours of the prostate and bladder. During this time, significant new …

Urothelial carcinoma of the bladder comprises two long-recognized disease entities with
distinct molecular features and clinical outcome. Low-grade non-muscle-invasive tumours …

Urothelial carcinoma of the bladder is unique among epithelial carcinomas in its divergent
pathways of tumorigenesis. Low-grade papillary tumours rarely become muscle-invasive …

Urothelial cancer has served as one of the most important sources of information about the
mutational events that underlie the development of human solid malignancies. Although …

Bladder cancer is one of the most prevalent cancers worldwide. Unfortunately, there have
been few advances in its clinical management due to a poor understanding of the …

Background Somatic genetic CDKN2A, TP53, and DNA content abnormalities are common
in many human cancers and their precursors, including esophageal adenocarcinoma (EA) …

To define the genetic changes of flat urothelial lesions, carcinoma in situ (CIS) and moderate
dysplasias (DII) were investigated for alterations in the two chromosomal regions most …

Activating point mutations in the FGFR3 gene occur frequently in low‐grade and low‐stage
bladder carcinomas, whereas they are rare in high‐grade carcinomas. This study …

Abstract The Genitourinary Pathology Society (GUPS) undertook a critical review of the
recent advances in bladder neoplasia with a focus on issues relevant to the practicing …